Enhertu Adverse Reactions


Daiichi Sankyo




Daiichi Sankyo
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Adverse Reactions
Summary of the safety profile: The most common adverse reactions were nausea (79.9%), fatigue (60.3%), vomiting (48.7%), alopecia (46.2%), constipation (35.9%), decreased appetite (34.6%), anaemia (33.8%), neutropenia (32.5%), diarrhoea (30.8%), thrombocytopenia (23.1%), cough (21.4%), leukopenia (20.5%), and headache (20.1%).
The most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v.4.03) Grade ≥ 3 adverse reactions were neutropenia (18.8%), anaemia (9.0%), nausea (6.8%), fatigue (6.4%), leukopenia (5.6%), lymphopenia (5.1%), vomiting (4.3%), thrombocytopenia (4.3%), hypokalaemia (3.4%), interstitial lung disease (ILD, 3.0%), diarrhoea (2.6%), febrile neutropenia (1.7%), dyspnoea (1.7%), abdominal pain (1.3%), decreased appetite (1.3%), and alanine aminotransferase increased (1.3%). In 2.6% of patients, ILD led to death.
Dose interruptions due to adverse reactions occurred in 27% of patients treated with Enhertu. The most frequent adverse reactions associated with dose interruption were neutropenia (14.5%), anaemia (3.4%), upper respiratory tract infection (3.0%), leukopenia (3.0%), ILD (2.6%), thrombocytopenia (2.6%), and fatigue (2.1%). Dose reductions occurred in 15% of patients treated with Enhertu. The most frequent adverse reactions associated with dose reduction were fatigue (3.8%), nausea (3.4%), and neutropenia (3.4%). Discontinuation of therapy due to an adverse reaction occurred in 12% of patients treated with Enhertu. The most frequent adverse reaction associated with permanent discontinuation was ILD (9.4%).
Tabulated list of adverse reactions: The safety of Enhertu has been evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of Enhertu 5.4 mg/kg in clinical studies. The median duration of exposure to Enhertu was 9.8 months (range: 0.7 to 37.1 months).
The adverse reactions in patients who received at least one dose of Enhertu in clinical studies are presented in Table 4. The adverse reactions are listed by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. (See Table 4.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Interstitial lung disease: In clinical studies (n = 234), ILD occurred in 15.0% of patients. Most ILD cases were Grade 1 (3.0%), Grade 2 (8.5%) or Grade 3 (0.4%). Grade 5 events occurred in 3.0% of patients. Median time to first onset was 5.5 months (range: 1.2 to 20.8) (see Dosage & Administration and Precautions).
Neutropenia: In clinical studies (n = 234), a decrease in neutrophil count was reported in 32.5% of patients and 18.8% had Grade 3 or 4 events. Median time of onset was 53 days (range: 8 days to 18.0 months), and median duration of the first event was 22 days (range: 2 days to 9.0 months). Febrile neutropenia was reported in 1.7% of patients (see Dosage & Administration).
Immunogenicity: As with all therapeutic proteins, there is a potential for immunogenicity. Across all doses evaluated in clinical studies, 0.6% (4/640) of evaluable patients developed antibodies against trastuzumab deruxtecan following treatment with Enhertu. There was no association between development of antibodies and allergic-type reactions.
Paediatric population: Safety has not been established in this population.
Elderly: Of the 234 patients with HER2-positive breast cancer treated with Enhertu 5.4 mg/kg, 26% were 65 years or older and 5% were 75 years or older. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged 65 years or older (49%) as compared to younger patients (39%), leading to more discontinuations due to adverse reactions.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in